Shah Pratik
Insider CIK 1580787 · OCRX Director, 10% owner · ASPX President and CEO, Director · THOR Director · SPRY Director, 10% owner · DSGN President, CEO and Chairperson, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2026-06-24 | 2026-06-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2026-01-02 | 2026-01-05 | 750,000 | — | $0 | 750,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2025-12-09 | 2025-12-11 | 525,000 | — | $0 | 525,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2025-12-09 | 2025-12-11 | 525,000 | — | $0 | 525,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2025-11-12 | 2025-11-14 | 250,000 | — | $0 | 4,574,554 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2025-11-12 | 2025-11-14 | 100,000 | — | $0 | 4,474,554 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2025-06-25 | 2025-06-27 | 30,000 | — | $0 | 30,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2025-01-02 | 2025-01-06 | 600,000 | — | $0 | 600,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2024-06-20 | 2024-06-24 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2024-06-13 | 2024-06-17 | 200,000 | — | $0 | 1,132,900 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2024-06-13 | 2024-06-17 | 1,132,900 | — | $0 | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2024-06-07 | 2024-06-07 | 1,332,950 | — | $0 | 4,824,554 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2024-06-04 | 2024-06-06 | 1,332,900 | — | $0 | 6,157,504 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | G Gift | 2024-06-04 | 2024-06-06 | 1,332,900 | — | $0 | 1,332,900 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | J Other | 2024-06-04 | 2024-06-06 | 2,665,800 | — | $0 | 7,490,404 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | J Other | 2024-06-04 | 2024-06-07 | 2,665,800 | — | $0 | 7,490,404 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2023-09-01 | 2023-09-05 | 525,000 | — | $0 | 525,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2023-09-01 | 2023-09-05 | 525,000 | — | $0 | 525,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2023-09-01 | 2023-09-05 | 1,050,000 | — | $0 | 1,050,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2023-06-27 | 2023-06-28 | 40,000 | — | $0 | 40,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2023-02-01 | 2023-02-03 | 415,000 | — | $0 | 415,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2022-11-08 | 2022-11-10 | 354,570 | — | $0 | 354,570 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award | 2022-11-08 | 2022-11-10 | 10,156,204 | — | $0 | 10,156,204 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2022-02-01 | 2022-02-02 | 475,000 | — | $0 | 475,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 171,025 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2021-03-30 | 2021-04-01 | 25,000 | $20.00 | $500.0K | 25,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 104,923 | — | $0 | 129,923 | SEC↗ |
| THOR Synthorx, Inc. | D To issuer deriv | 2020-01-23 | 2020-01-24 | 10,223 | $55.60 | $568.4K | 0 | SEC↗ |
| THOR Synthorx, Inc. | U Tender | 2020-01-23 | 2020-01-24 | 62,412 | $68.00 | $4.24M | 0 | SEC↗ |
| THOR Synthorx, Inc. | A Award deriv | 2019-06-07 | 2019-06-10 | 10,223 | — | $0 | 10,223 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | D To issuer deriv | 2015-05-05 | 2015-05-06 | 200,000 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | D To issuer deriv | 2015-05-05 | 2015-05-06 | 215,153 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | D To issuer deriv | 2015-05-05 | 2015-05-06 | 100,000 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | U Tender | 2015-05-05 | 2015-05-06 | 903,018 | — | $0 | 0 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | A Award deriv | 2015-02-02 | 2015-02-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | A Award deriv | 2015-02-02 | 2015-02-04 | 200,000 | — | $0 | 200,000 | SEC↗ |
| ASPX Auspex Pharmaceuticals, In | P Buy | 2014-02-10 | 2014-02-12 | 8,333 | $12.00 | $100.0K | 903,018 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2013-08-30 | 2013-12-23 | 20,000 | — | $0 | 20,000 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | J Other | 2013-07-15 | 2013-07-17 | 1,675,677 | $6.00 | $10.05M | 1,675,677 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | J Other | 2013-07-15 | 2013-07-17 | 762,892 | $6.00 | $4.58M | 762,892 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2012-10-01 | 2013-07-17 | 161,855 | $44.23 | $7.16M | 161,855 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2012-08-07 | 2013-07-17 | 31,835 | — | $0 | 31,835 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2012-03-30 | 2013-07-17 | 161,855 | $44.23 | $7.16M | 161,855 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2011-04-19 | 2013-07-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2010-02-11 | 2013-07-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2009-02-11 | 2013-07-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| OCRX Ocera Therapeutics, Inc. | A Award deriv | 2006-02-06 | 2013-07-17 | 100,000 | — | $0 | 100,000 | SEC↗ |